Navigation Links
UPCI Joins ExCell Research Study Using Stem Cells for Leukemia and Lymphoma Patients
Date:6/15/2009

PITTSBURGH, Pennsylvania, and JERUSALEM, Israel, June 15 /PRNewswire/ -- The University of Pittsburgh Cancer Institute (UPCI) and the Gamida Cell - Teva Joint Venture announced today that the Institute has joined an elite group of cancer centers in Europe, the United States and Israel that are now enrolling patients to participate in the ExCell research study.

The phase III study is assessing the safety and efficacy of StemEx(R), an investigational product derived from stem cells, as an alternative treatment to bone marrow transplants for hematological malignancies, including leukemia and lymphoma. StemEx is a graft of expanded stem/progenitor cells taken from a single unit of umbilical cord blood and then transplanted in combination with non-expanded cells from the same unit.

"I am extremely pleased UPCI has the opportunity to be a part of this study," said Mounzer Agha, M.D., clinical director of UPCI's Hematopoietic Stem Cell Transplant Program. "Using umbilical cord blood stem cells instead of a traditional bone marrow transplant opens tremendous treatment possibilities for patients with diseases like leukemia and lymphoma."

Bone marrow transplantation is a life-saving treatment for many types of leukemia and lymphoma. However, more than half the number of patients in need of a transplant can't find matching bone marrow donors. Cord blood could be an alternative of choice.

Previous research has shown that umbilical cord blood stem cells offer a viable therapeutic option for leukemia and lymphoma patients without the necessity of a matched donor. Umbilical cord blood has two important advantages - it is a readily available source for stem cells and it has a lower matching requirement for patients. With StemEx(R), the cord blood unit is enriched with stem cells, which are critical for a successful transplantation.

"We are pleased to work with the able and highly experienced team at UPCI led by Dr. Agha. They join an extraordinary group of cord blood cancer centers currently recruiting patients for the ExCell trial. Everyone on the international ExCell clinical team shares the same goal - to validate the therapeutic potential of StemEx as a treatment for blood cancers," said David Snyder, M.D., vice president of clinical development at Gamida Cell.

About UPCI

Founded in 1984, the University of Pittsburgh Cancer Institute became a National Cancer Institute (NCI)-designated Comprehensive Cancer Center in 1990. UPCI, the only cancer center in western Pennsylvania with this elite designation, serves the region's population of more than 6 million. Presently, UPCI receives a total of $154 million in research grants and is ranked 10th in funding from the NCI.

About Gamida Cell

Gamida Cell Ltd. is a world leader in stem cell expansion technologies and therapeutic products. The company is developing a pipeline of products in stem cell transplantation and in tissue regeneration to effectively treat debilitating and often fatal illnesses such as cancer, hematological, autoimmune and ischemic diseases. Gamida Cell's therapeutic candidates contain populations of adult stem cells, selected from non-controversial sources such as umbilical cord blood and bone marrow, which are expanded in culture. Gamida Cell was successful in translating these proprietary expansion technologies into robust and validated manufacturing processes under GMP. Gamida Cell's flagship product, StemEx, is now being studied as a therapy for patients with blood cancers in an international pivotal trial at leading transplant centers in the U.S., Europe and Israel. StemEx has orphan drug designation in the U.S. and in Europe. Gamida Cell's current shareholders include: Elbit Imaging, Biomedical Investment, Israel Healthcare Venture, Teva Pharmaceuticals, Amgen, Denali Ventures and Auriga Ventures.

    CONTACT:

    Courtney McCrimmon
    Wendy Zellner
    UPMC Media Relations
    PHONE: +1-412-647-3555
    E-MAIL: McCrimmonCP@upmc.edu
            ZellnerWL@upmc.edu

    CONTACT: Marjie Hadad
    Gamida Cell
    PHONE: +972-54-536-5220
    E-MAIL: marjie@gamida-cell.com



'/>"/>
SOURCE Gamida Cell LTD
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine
2. BARC Central Laboratory Joins Alzheimers Association Research Roundtable
3. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
4. Photos: Sentara Joins 4 U.S. Hospitals in International TARGIT Breast Cancer Trial
5. Leading Cardiologist Joins Ontario Research Firm to Conduct New Clinical Trial on the Effect of Pantethine on Cholesterol Levels
6. Vincent W. Renz Joins NewCardio as President
7. Judith Quinlan Joins Cytel as Vice President, Adaptive Trials
8. Dr. Peter Nash, Ph.D. Joins Mach One Corporation as Chief Scientist
9. Dr. Harriet Robinson Joins GeoVax Team as V.P. of R & D to Accelerate AIDS Vaccine Trials Program
10. Dr. Rajeev Venkayya Joins Gates Foundation as Director of Global Health Delivery
11. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic ... World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. ... some of the world’s leading providers of cereal and other breakfast foods. Its residents ...
(Date:6/26/2016)... Cary, North Carolina (PRWEB) , ... June 26, 2016 , ... ... the release of a new product that was developed to enhance the health of ... harvested for centuries. , The two main herbs in the PawPaws Cat Kidney ...
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
(Date:6/25/2016)... ... 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can ... CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn ... X . Simply select a ProHand generator and drag it above media or text ...
Breaking Medicine News(10 mins):